Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy

被引：0
|
作者：
Golshayan, A. [1 ]
Choueiri, T. K. [1 ]
Elson, P. [1 ]
Garcia, J. A. [1 ]
Khaswneh, M. [1 ]
Usman, S. [1 ]
Tamaskar, I. [1 ]
Wood, L. [1 ]
Rini, B. I. [1 ]
Bukowski, R. M. [1 ]
机构：
[1] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5046
引用
收藏
页数：1
相关论文
共 50 条
  • [21] VEGF-targeted therapy in renal cell carcinoma: Active drugs and active choices
    Rini B.I.
    Current Oncology Reports, 2006, 8 (2) : 85 - 89
  • [22] Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
    Gruenwald, V.
    Seidel, C.
    Fenner, M.
    Ganser, A.
    Busch, J.
    Weikert, S.
    BRITISH JOURNAL OF CANCER, 2011, 105 (11) : 1635 - 1639
  • [23] Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
    V Grünwald
    C Seidel
    M Fenner
    A Ganser
    J Busch
    S Weikert
    British Journal of Cancer, 2011, 105 : 1635 - 1639
  • [24] Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy
    Richey, S. L.
    Culp, S. H.
    Jonasch, E.
    Corn, P. G.
    Pagliaro, L. C.
    Tamboli, P.
    Patel, K. K.
    Matin, S. F.
    Wood, C. G.
    Tannir, N. M.
    ANNALS OF ONCOLOGY, 2011, 22 (05) : 1048 - 1053
  • [25] Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors
    Cho, Daniel C.
    ONCOTARGETS AND THERAPY, 2013, 6 : 679 - 684
  • [26] Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients?
    Zhang, Guiming
    Zhu, Yao
    Dong, Dahai
    Gu, Weijie
    Zhang, Hailiang
    Sun, Lijiang
    Ye, Dingwei
    ONCOTARGETS AND THERAPY, 2014, 7 : 2043 - 2052
  • [27] The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).
    Fay, Andre Poisl
    de Velasco, Guillermo
    Gray, Kathryn P.
    Ho, Thai Huu
    Song, Jiaxi
    Kapur, Payal
    Albiges, Laurence
    McDermott, David F.
    Heng, Daniel Yick Chin
    Brugarolas, James
    Choueiri, Toni K.
    Signoretti, Sabina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [28] Predictive factors associated with clinical outcome and safety in Korean patients with metastatic renal cell carcinoma treated with sunitinib
    Miller, L.
    Lal, L. S.
    Tannir, N. M.
    Byfield, S. DaCosta
    Atkinson, B.
    Feng, C.
    Lau, J. K.
    Yin, L.
    Jonasch, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Risk factors and a model to predict toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: Results from the International Metastatic RCC Database Consortium
    Kaymakcalan, Marina Dusevic
    Xie, Wanling
    Albiges, Laurence
    North, Scott A.
    Kollmannsberger, Christian K.
    Smoragiewicz, Martin
    Kroeger, Nils
    Wells, Connor
    Rha, Sun Young
    Lee, Jae-Lyun
    Fay, Andre Poisl
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [30] CLINICAL PROGNOSTIC FACTORS ASSOCIATED WITH OUTCOME IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED WITH ANTIANGIOGENIC AGENTS
    Bracarda, S.
    De Angelis, V.
    Caserta, C.
    Rossi, M.
    Hamzaj, A.
    Crino, L.
    ANNALS OF ONCOLOGY, 2008, 19 : 195 - 195
12345